Janus kinase-3 dependent inflammatory responses in allergic asthma
Rama Malaviya1, Debra L Laskin, Ravi Malaviya
1Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA. malaviya@rci.rutgers.edu
International Immunopharmacology
|May 1, 2010
Summary
Targeting Janus kinase (JAK)-3 offers a promising strategy to manage allergic asthma by controlling key inflammatory cells. This approach aims to mitigate the chronic lung inflammation characteristic of this condition.
Area of Science:
- Immunology
- Pulmonology
- Cell Biology
Background:
- Allergic asthma is a chronic inflammatory lung disease involving airway obstruction and elevated immunoglobulin E (IgE).
- Pathogenesis involves multiple immune cells, including mast cells, T cells, macrophages, and dendritic cells.
- Janus kinase (JAK)-3 is a critical non-receptor tyrosine kinase involved in cytokine signaling pathways.
Purpose of the Study:
- To review the role of JAK-3 in the pathogenic processes of allergic asthma.
- To explore JAK-3 as a potential therapeutic target for allergic asthma.
Main Methods:
- Literature review focusing on JAK-3's function in immune cell regulation.
- Analysis of JAK-3's involvement in cytokine signaling relevant to asthma.
Main Results:
- JAK-3 regulates the functional responses of key immune cells implicated in allergic asthma.
- JAK-3 plays a significant role in mediating inflammatory processes within the airways.
Conclusions:
- Targeting JAK-3 is a rational therapeutic strategy for allergic asthma.
- Inhibiting JAK-3 may control inflammatory responses from multiple cell types involved in asthma pathogenesis.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.